Israel Manzanedo1, Fernando Pereira2, Estíbalitz Pérez-Viejo2, Ángel Serrano2, Miguel Hernández-García3, Beatriz Martínez-Torres3, Cristina Rihuete-Caro3, Julia Calzas4, Margarita Cueto5. 1. Peritoneal Carcinomatosis Unit, Department of General and Digestive Surgery, Fuenlabrada University Hospital, Fuenlabrada, Madrid, Spain - israel.manzanedo@salud.madrid.org. 2. Peritoneal Carcinomatosis Unit, Department of General and Digestive Surgery, Fuenlabrada University Hospital, Fuenlabrada, Madrid, Spain. 3. Department of General and Digestive Surgery, Fuenlabrada University Hospital, Fuenlabrada, Madrid, Spain. 4. Department of Medical Oncology, Fuenlabrada University Hospital, Fuenlabrada, Madrid, Spain. 5. Department of Obstetrics and Gynecology, Fuenlabrada University Hospital, Fuenlabrada, Madrid, Spain.
Abstract
BACKGROUND: Peritoneal dissemination is the most common route of spread of epithelial ovarian cancer (EOC). Cytoreductive surgery (CRS) followed by platinum-based systemic chemotherapy is the current standard treatment in advanced stages, with suboptimal results. The aim of this study is to analyze the outcome of advanced EOC treated with CRS plus hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) combined with systemic chemotherapy. METHODS: We analyze a cohort of women treated with CRS plus HIPEC for peritoneal carcinomatosis secondary to EOC from May 2007 to December 2014. We included both patients with peritoneal disease at first diagnosis of EOC and peritoneal recurrences after initial treatment. RESULTS: We performed 61 CRS with HIPEC procedures, 31 cases as primary treatment (4 as upfront therapy and 27 after neoadjuvant chemotherapy) and 30 as secondary treatment (recurrences). Median Peritoneal Carcinomatosis Index (PCI) was 9; the cytoreduction was optimal in 92% of the procedures. Severe morbidity (Grade III-IV of Clavien-Dindo classification) was 29.5%, without mortality. Median follow-up was 23 months and median disease-free survival (DFS) was 14 months (14 in primary surgery group and 17 in recurrence group, P=0.51). Median overall survival (OS) was 57 months; in primary surgery group, OS was 96.8% at 1 year, and 55% at 5 years, and median OS was not reached; OS in recurrence group was 89.3% at 1 year and 47.1% at 5 years, and median OS was 57 months. CONCLUSIONS: CRS with HIPEC is a treatment option for EOC with good results in terms of morbidity and survival, in experienced centers.
BACKGROUND: Peritoneal dissemination is the most common route of spread of epithelial ovarian cancer (EOC). Cytoreductive surgery (CRS) followed by platinum-based systemic chemotherapy is the current standard treatment in advanced stages, with suboptimal results. The aim of this study is to analyze the outcome of advanced EOC treated with CRS plus hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) combined with systemic chemotherapy. METHODS: We analyze a cohort of women treated with CRS plus HIPEC for peritoneal carcinomatosis secondary to EOC from May 2007 to December 2014. We included both patients with peritoneal disease at first diagnosis of EOC and peritoneal recurrences after initial treatment. RESULTS: We performed 61 CRS with HIPEC procedures, 31 cases as primary treatment (4 as upfront therapy and 27 after neoadjuvant chemotherapy) and 30 as secondary treatment (recurrences). Median Peritoneal Carcinomatosis Index (PCI) was 9; the cytoreduction was optimal in 92% of the procedures. Severe morbidity (Grade III-IV of Clavien-Dindo classification) was 29.5%, without mortality. Median follow-up was 23 months and median disease-free survival (DFS) was 14 months (14 in primary surgery group and 17 in recurrence group, P=0.51). Median overall survival (OS) was 57 months; in primary surgery group, OS was 96.8% at 1 year, and 55% at 5 years, and median OS was not reached; OS in recurrence group was 89.3% at 1 year and 47.1% at 5 years, and median OS was 57 months. CONCLUSIONS: CRS with HIPEC is a treatment option for EOC with good results in terms of morbidity and survival, in experienced centers.
Authors: I Manzanedo; F Pereira; Á Serrano; E Pérez-Viejo; B Martínez-Torres; L Carrión; J Calzas Journal: Clin Transl Oncol Date: 2019-02-20 Impact factor: 3.405
Authors: Helena C Bartels; Ailin C Rogers; James Postle; Conor Shields; Jurgen Mulsow; John Conneely; Donal J Brennan Journal: Pleura Peritoneum Date: 2019-06-28